A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

Abstract Background In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolumab. Methods Eligible patients were ≥ 18 years old...

Full description

Bibliographic Details
Main Authors: Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avsar, Wen Hong Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Ales Diaz
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Cancer
Subjects:
Galunisertib
Immune checkpoint inhibitor
Nivolumab
NSCLC
TGF-β
Online Access:https://doi.org/10.1186/s12885-023-11153-1

Internet

https://doi.org/10.1186/s12885-023-11153-1

Similar Items